Cargando…

Add-on treatment with mirabegron may improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after tamsulosin monotherapy

BACKGROUND: The aim of this study was to evaluate the change in lower urinary tract symptoms and quality of life (QoL) after combination therapy of solifenacin and mirabegron in patients with benign prostatic hyperplasia presenting with persistent storage symptoms after treatment with tamsulosin. MA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Tae Wook, Chung, Hyun Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750565/ https://www.ncbi.nlm.nih.gov/pubmed/33414845 http://dx.doi.org/10.1177/1756287220974130

Ejemplares similares

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia
por: Zhou, Zhongbao, et al.
Publicado: (2019)

Short-term Effect of Tamsulosin and Finasteride Monotherapy and their Combination on Nigerian Men with Benign Prostatic Hyperplasia
por: Odusanya, Benjamin O, et al.
Publicado: (2017)

Effects of Tamsulosin on Premature Ejaculation in Men with Benign Prostatic Hyperplasia
por: Choi, Jae Hwi, et al.
Publicado: (2014)

The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis
por: Su, Shunye, et al.
Publicado: (2020)

Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia
por: Chung, Jae-Wook, et al.
Publicado: (2011)

Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study
por: Kakizaki, Hidehiro, et al.
Publicado: (2020)

Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder
por: Wang, Hui, et al.
Publicado: (2017)

Evaluation of intermittent tamsulosin in treating symptomatic patients with benign prostatic hyperplasia
por: Soliman, Mohamed G., et al.
Publicado: (2023)

Cost-Effectiveness of Tamsulosin, Doxazosin, and Terazosin in the Treatment of Benign Prostatic Hyperplasia
por: Ohsfeldt, Robert L., et al.
Publicado: (2004)

Efficacy of combination therapy with tamsulosin and zolpidem on nocturia in patients with benign prostatic hyperplasia
por: Miwa, Kousei, et al.
Publicado: (2011)

Dutasteride plus Tamsulosin fixed-dose combination first-line therapy versus Tamsulosin Monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting
por: Geitona, Maria, et al.
Publicado: (2014)

Relation of baseline prostate volume to improvement of lower urinary tract symptoms due to tamsulosin monotherapy in benign prostatic hyperplasia: An exploratory, multicenter, prospective study
por: El-Adawy, Mahmoud Shoukry, et al.
Publicado: (2020)

Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: A randomised, double-blind, placebo-controlled trial
por: Fawzi, Amr, et al.
Publicado: (2016)

Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial
por: Pande, Satabdi, et al.
Publicado: (2014)

Add-on Therapy With the α-Blockers Tamsulosin and Naftopidil Improves Voiding Function by Enhancing Neuronal Activity in Prostatic Hyperplasia Rats
por: Ko, Il-Gyu, et al.
Publicado: (2018)

Effects of Low-Dose Tamsulosin on Sexual Function in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
por: Kim, Sin Wook, et al.
Publicado: (2013)

Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study
por: Kwon, Se Yun, et al.
Publicado: (2020)

Impact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile Function
por: Seo, Deok Ha, et al.
Publicado: (2011)

Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients
por: Kim, Su Jin, et al.
Publicado: (2017)

Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction
por: Ahn, Sun Tae, et al.
Publicado: (2020)

Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia
por: Griwan, Mahavir Singh, et al.
Publicado: (2014)

Beneficial Effect of Increasing the Dose of Tamsulosin to 0.4 mg in Japanese Patients with Benign Prostatic Hyperplasia
por: Hirose, Yasuhiko, et al.
Publicado: (2011)

Additive effect of oral LDD175 to tamsulosin and finasteride in a benign prostate hyperplasia rat model
por: Choi, Bo Ram, et al.
Publicado: (2018)

Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis
por: Cai, Tong, et al.
Publicado: (2020)

Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability
por: Barkin, Jack
Publicado: (2011)

Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin
por: Djavan, Bob, et al.
Publicado: (2011)

A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia
por: Manjunatha, R., et al.
Publicado: (2016)

Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
por: Eisen, Christoph, et al.
Publicado: (2020)

The Authors Reply: Reply on “Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients”
por: Kim, Su Jin, et al.
Publicado: (2017)

A 52‐week multicenter randomized controlled study of the efficacy and safety of add‐on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study)
por: Yamanishi, Tomonori, et al.
Publicado: (2018)

Efficacy of 0.4 mg tamsulosin monotherapy in patients with moderate-to-severe lower urinary tract symptoms
por: Kang, Tae Wook, et al.
Publicado: (2021)

Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post‐marketing study
por: Takahashi, Satoru, et al.
Publicado: (2020)

Cardiovascular safety of mirabegron add‐on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study
por: Katoh, Takao, et al.
Publicado: (2020)

Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis
por: Sun, Kai, et al.
Publicado: (2020)

Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis
por: Chai, Yumeng, et al.
Publicado: (2021)

Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia
por: Dimitropoulos, Konstantinos, et al.
Publicado: (2015)

Non-Invasive Predictors of Response to Tamsulosin for Benign Prostatic Obstruction
por: Shoaib, Mohammad, et al.
Publicado: (2021)

Prospective Factor Analysis of Alpha Blocker Monotherapy Failure in Benign Prostatic Hyperplasia
por: Hong, Kyoung Pyo, et al.
Publicado: (2010)

A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model
por: Udeh, Emeka I., et al.
Publicado: (2016)

A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia
por: Cao, Yanwei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_i1u3q9902b3kum4e2qa61k73va